Collaboration intended to enable faster market delivery time for life-threatening disease medications.
Cognizant, an information technology (IT) company, and Gilead, a biopharma organization, announced a five-year expansion to their current partnership. As per the deal, Cognizant will manage Gilead's global IT infrastructure, platforms, applications and advanced analytics, and lead initiatives designed to accelerate its digital transformation, according to a company press release. The main goal of the partnership is to provide Gilead with the ability to streamline business in order to release medicines for life-threatening illnesses at a faster pace.
"We're excited about this expanded partnership with Gilead, one of the pharmaceutical industry leaders in adapting advanced technologies to better deliver transformative treatments for patients world-wide," said Surya Gummadi, EVP, President, Cognizant Americas. "Working together our teams will be leveraging the latest technologies from automation to cloud computing, and Generative AI to help Gilead bring its products to market faster, more efficiently, and with higher customer satisfaction."
References: Cognizant and Gilead Extend Partnership with Five-Year Service Agreement Estimated at $800 Million. PR Newswire. July 24, 2023. Accessed July 25, 2023. https://www.prnewswire.com/news-releases/cognizant-and-gilead-extend-partnership-with-five-year-service-agreement-estimated-at-800-million-301883522.html
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.